Crowdonomics
WatchlistPortfolio
NovaXS Biotech Corp.

Reg CF · SAFE · Dec 2022

ClosedReached targetReg CFSAFE
via Republic · last checked Oct 8, 2026View campaign
Raised
$114.2K / $1.2M max
9% of ceiling · target hit day 3
Investors
231
$494.3 avg
Valuation cap
$14M
cap, not an agreed valuation

Raised over time

Cumulative raisedInvestors
$114K$57K$0
2291150
Dec 9, 2022 · openedFeb 4, 2023 · last reading
Target ($25K) hit — Dec 12, 2022, day 3Deadline Feb 3, 2023

Left axis: cumulative dollars raised. Right axis: cumulative investors. Live figures via Republic, last checked Oct 8, 2026; investor counts may lag the platform by up to a day.

Financials disclosed in this offering

FY2020–FY2021 · hover for source
$0
FY2020
$0
−$62K
FY2021
RevenueNet income
Metric
FY2020 reviewed*
FY2021 unaudited
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
$0
-$62,494
Taxes paid
$0
$0
Balance sheet
Cash
$0
$297,216
Accounts receivable
$0
$0
Total assets
$0
$297,216
Short-term debt
$0
$7,872
Long-term debt
$0
$290,000
Total liabilities
$0
$297,872
Other
Headcount
—
5

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Deal terms

Valuation cap$14M
Conversion discount20%

Perks

Invest $1,500, receive a 15-minute call with the founders$1.5K+

Offering details

Target$25,000
Max$1,235,000
Min investment$100
OpenedDec 9, 2022
DeadlineFeb 3, 2023
ClosedFeb 3, 2023
Days active56

Links & provenance

Campaign pageSEC filing
Source: Manual
0001946145-22-000001
Last synced Aug 19, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.